Home

David W. Nassif

CIK 1636975 · CFO / CLO · last filed 2026-05-26

David W. Nassif is a CFO / CLO who has filed 16 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing shows the insider sold $303.1K of PHVS on May 26, 2026. Across all open-market trades the lifetime net is −$402.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.91M

Companies

4

Total Filings

16

Lifetime Open-Market Net

-$402.8K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PHVS CFO / CLO 120,300 $32.48 $3.91M -$303.1K 1 2026-05-26
Sio Gene Therapies Inc. (SIOX) Delisted Interim CEO, CFO 51,538 $0.48 $24.6K $0 4 2022-02-10
Sio Gene Therapies Inc. (AXGT) Delisted Principal Financial Officer 18,944 — — $0 4 2020-06-15
SteadyMed Ltd. (STDY) Delisted EVP and CFO 22,157 — — -$99.7K 5 2018-07-09

Recent Filings

16 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-26 PHVS Sell (S) −10,000 -$303.1K EDGAR
2026-05-21 PHVS Notice (144) −10,000 -$303.1K EDGAR
2022-02-10 Sio Gene Therapies Inc. (SIOX) Delisted Grant (A) — $0 EDGAR
2021-12-09 Sio Gene Therapies Inc. (SIOX) Delisted Mixed +11,240 -$8.9K EDGAR
2021-04-19 Sio Gene Therapies Inc. (SIOX) Delisted Grant (A) — $0 EDGAR
2021-03-22 Sio Gene Therapies Inc. (SIOX) Delisted Mixed +15,060 $0 EDGAR
2020-06-15 Sio Gene Therapies Inc. (AXGT) Delisted Mixed +9,794 -$17.1K EDGAR
2020-04-17 Sio Gene Therapies Inc. (AXGT) Delisted Grant (A) — $0 EDGAR
2019-09-24 Sio Gene Therapies Inc. (AXGT) Delisted Grant (A) — $0 EDGAR
2019-07-02 Sio Gene Therapies Inc. (AXGT) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 16
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.